Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONO-6414
- Development stage
- Phase 1
- Lead developer
- Ono Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ONO-6414 is an orally bioavailable, selective small molecule antagonist of the **Prostaglandin E2 receptor 4 (EP4)**, currently under development by **Ono Pharmaceutical**. It is being evaluated in Phase 1 clinical trials for the treatment of **ulcerative colitis**. While PGE2-EP4 signaling is traditionally associated with mucosal protection, it also plays a role in promoting Th1 and Th17 cell-mediated inflammation and the production of inflammatory cytokines like IL-23. By antagonizing the EP4 receptor, ONO-6414 aims to modulate these inflammatory pathways and provide a novel therapeutic approach for patients with active ulcerative colitis.
02
Targets
PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on ONO-6414.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONO-6414.